MedPath

The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000019071
Lead Sponsor
Tokyo Medical and Dental University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are taking SGLT2 inhibitors Patients with insulin treatment Patients with severe diabetic retinopathy Patients who are hypersensitive to SGLT2 inhibitors Patients with cogestive heart failure (NYHA classification class III or IV) Patients with active infection, malignancy, severe liver or renal diseases Patients who had recently received operation or had severe trauma Patients who had experienced atherothrombotic events including myocardila infarction and/or stroke Patients with severe ketosis or diabetic coma/pre-coma Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients who were judged inadequate to enroll in the study by medical doctors

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The change of epicaridial fat volume from baseline at 12 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath